Ribociclib plus hormone therapy for advanced breast cancer
Part of Cancer clinical trials.
This trial tests a new approach: starting with a targeted pill (ribociclib) plus hormone therapy (an aromatase inhibitor), instead of immediate chemotherapy, for women with a specific type of breast cancer (ER low-positive, HER2-negative) that is growing quickly. If eligible, you would not have received any prior treatment for your advanced cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older.
- Your cancer is ER-positive with between 10% and 50% ER expression (a mid-low level) and HER2-negative.
- You have advanced or metastatic breast cancer that hasn't been treated yet for this stage.
- Your doctor says your disease is growing quickly (for example, causing symptoms in your organs).
- You have not taken a CDK4/6 inhibitor like ribociclib before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at how well ribociclib works and why it may stop working over time in people with advanced, hormone-receptor–positive, HER2-negative breast cancer. It also analyzes blood and tissue samples to help researchers understand resistance patterns and improve future treatment decisions.
This trial tests adding ribociclib (a targeted pill) to standard hormone therapy for people with early but high-risk HR-positive, HER2-negative breast cancer, after surgery.
This trial tests a new combination of ribociclib and anastrozole as a first treatment for advanced hormone receptor-positive, HER2-negative breast cancer that has not been treated before. It may help if you have not received any prior therapy for metastatic disease.
This trial tests whether adding ribociclib (a targeted pill) to hormone therapy can control breast cancer that has come back in the breast area or nearby lymph nodes/chest wall. It targets hormone-receptor–positive and HER2-negative tumors to help slow disease after local treatment.
This trial tests ribociclib, a targeted therapy, for women with hormone receptor-positive, HER2-negative breast cancer who still have cancer cells in the breast or lymph nodes after initial chemotherapy. It aims to reduce the chance of cancer coming back.
This trial studies whether adding ribociclib to standard hormone (endocrine) therapy lowers the risk of breast cancer coming back in early-stage, hormone-receptor–positive cancer. It mainly looks at safety and how well the treatment controls cancer after surgery and (sometimes) prior hormone treatment.
Hear when a new Advanced Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.